Should you cover Wegovy or Mounjaro at work?

If you run Benefits, or you're the person who owns Reward, this topic has a way of landing on your desk with zero warning.

One minute it's a few employee questions. Next minute it's on the renewal call agenda. Then someone senior asks: "What's our position on this?"

So let's make it easier.

This guide is for UK employers who want a sensible policy on GLP-1 medicines (like Wegovy and Mounjaro), without turning it into a never-ending debate, or a privacy mess.

Two things you're probably feeling already:

• You're getting hit at renewal and you need levers you can pull in-quarter.
• You need proof you can show internally, and you need it without your workforce feeling watched.

Last updated: 15 February 2026

Why this is suddenly on your agenda

Because the market moved.

Howden published UK employer research in January 2026 saying demand is already here and employers are having to rethink plan design and budgets because of it.

And insurers are building offers around it. For example, Bupa announced that corporate customers can choose to enhance schemes to cover weight management services and the cost of medications from January 2026 renewals.

So even if your stance is "we're not covering this right now", you still need a position. Otherwise your position becomes "we'll deal with it case by case", which is usually the worst of both worlds.

Quick reset on GLP-1 medicines

GLP-1 medicines are prescription medicines licensed for specific medical conditions. The MHRA is clear they should be used within their licensed indications, and not for cosmetic or aesthetic weight loss.

That's the anchor.

You're not trying to become a clinical service as an employer. You're trying to decide what you will fund (if anything), and what "safe and fair" looks like if you do.

Start with the real question

Before you argue about Wegovy vs Mounjaro vs "should we cover anything", pick the problem you're trying to solve.

Most employers fall into one of these:

• Renewal pressure and repeat cost — You're seeing the same patterns again and again (often linked to weight-related risk), and you want to change the curve.
• Employee health and function — You want people to feel better day-to-day, and you want fewer workdays lost over time.
• Fair access with sensible boundaries — You don't like the idea that only employees with cash can get support, but you also can't open the door with no rules.

Pick one main goal. Two is fine. If you pick three, the policy turns into a maze and nobody follows it.

Three policy options employers pick

Option 1: Don't cover GLP-1 medicines

This is the cleanest policy. It also means employees will still access them privately, and you may have no guardrails, no consistent support, and no way to learn what's happening in your population.

Some employers still choose this. If you do, the best move is to pair it with signposting: "If you're using these medicines, here's how to get safe support."

Option 2: Cover through a structured pathway

This is the middle ground that usually works best.

It means:

• eligibility rules (written down, applied consistently)
• clinical assessment through a regulated provider
• wraparound support (food, behaviour, side effects, mental health screening when appropriate)
• clear review points and stopping rules
• employer reporting that stays aggregated

It's also closer to how NICE frames these medicines: not as stand-alone injections, but as part of a weight management service with diet and physical activity support.

Option 3: Reimburse private purchases

This is tempting because it looks simple: "buy it yourself, we'll pay a share." In practice it often creates a messy setup you can't manage:

• different prescribing standards
• no consistent support
• no consistent reporting
• awkward "prove it" conversations that you don't want HR involved in

If you reimburse at all, it usually works better when reimbursement only applies inside a defined provider pathway (so you still have guardrails and governance).

Eligibility and guardrails you can copy

You want guardrails for three reasons: people understand the rules, the policy feels fair, and spend stays predictable.

Here's a straightforward approach you can adapt.

1) Keep it clinical, not cosmetic

Plain English works best:

• "This benefit is for employees who meet clinical criteria for weight management support."
• "It is not for cosmetic weight loss."

That aligns with MHRA messaging on licensed use and avoiding cosmetic use.

2) Start from NICE-style thresholds (then adapt)

NICE gives you a defensible baseline. You don't have to copy it, but it's hard to argue with as a starting point.

NICE semaglutide guidance includes BMI and comorbidity criteria and is framed within a specialist weight management service. NICE tirzepatide guidance includes BMI and comorbidity criteria and has a structured "continue or stop" decision point.

A simple employer-friendly way to write this:

• Eligibility is assessed clinically (BMI and weight-related health factors).
• Where NICE uses lower BMI thresholds for some ethnic groups, your pathway should recognise that too, because it matters for fairness.

3) Build in review points and stopping rules

This is how you avoid paying indefinitely with no signal.

NICE includes a practical stopping consideration for semaglutide if less than 5% of initial weight is lost after 6 months of treatment. NICE tirzepatide guidance also uses a 6-month review point on the highest tolerated dose to decide whether to continue, based on benefits and risks.

You don't need to copy/paste the rule. You do need a formal review point that's written down and followed.

4) Decide your boundary conditions upfront

Write these decisions into the policy so you don't end up doing one-off exceptions forever:

• Is the programme opt-in only? (Usually yes.)
• Is there a cap (per member per year, or a cohort cap)?
• Are you covering medication, support, or both?
• What happens if someone stops medication?
• How do you handle sensitive situations like pregnancy planning? (This should sit with clinicians, but your pathway needs a safe process.)

Cost modelling that Finance will accept

You won't get a perfect forecast. You can get a useful one.

Here's the simple model:

Annual cost = eligible population × expected uptake × average monthly cost × average months on programme

Then run 3 scenarios:

• conservative uptake
• expected uptake
• high uptake

The bit that usually gets missed: the more vague your policy is, the less predictable "months on programme" becomes. A structured pathway tends to make this more stable, because there's one set of review points and one set of rules.

Also, it's worth saying out loud: this spend is showing up because obesity-related conditions are already a cost driver and employers expect the impact to grow. So the decision is rarely "spend vs don't spend". It's "spend in a controlled way vs spend in an uncontrolled way".

How to measure impact without prying on members

If you want this to survive a renewal conversation, you need measures that are: useful, privacy-safe, and not easy to game.

A practical reporting pack from a provider can be aggregated and still meaningful.

What to ask for in monthly reporting

Aggregated reporting on:

• registrations and eligibility pass rate
• drop-off points (where people quit the process)
• support engagement (attendance counts, not session details)
• safety escalations as counts (not clinical content)
• outcomes as group summaries

If you have insurer reporting, you can layer in high-level utilisation trends over time. Keep it at group level.

What you should not ask for

• individual adherence
• individual clinical notes
• anything that risks identifying someone in a small team

If you want a simple principle: employers should manage the benefit; clinicians should manage the health data.

A pilot plan that works

Most pilots fail because they try to prove too much too fast.

Instead, aim for this:

• can we run it safely and fairly?
• do employees use it?
• do we see early signals that it's worth scaling?

A clean 10-week pilot shape:

• Weeks 0–2: Set the rules and the comms — agree eligibility, agree the pathway (assessment, prescribing where appropriate, support), write FAQs in plain language.
• Weeks 3–6: Enrol and onboard — open enrolment, track where people get stuck (this is gold for fixing rollout).
• Weeks 7–10: Stabilise and report — keep support steady, produce the first aggregated report, decide whether to stop, continue, or expand with changes.

This is the type of pilot we run with employers: structured support for employees using GLP-1 medicines, clean governance, and reporting you can actually use.

If you want to talk about a pilot, request a pilot here.

Questions to ask your insurer or provider

This is the part Benefits Managers care about, because it stops surprises later.

Clinical model

• Who does clinical assessment and prescribing?
• What are your screening steps and escalation routes?
• What are your review points and stopping rules?

Support model

• What support is included alongside medication?
• What is the off-ramp plan if someone stops medication?

Data and privacy

• Show me a sample employer dashboard.
• What minimum cohort sizes do you use for reporting?

Operational reality

• What does employee onboarding look like?
• What is the typical time from sign-up to first clinical touchpoint?

FAQ

Do we have to cover Wegovy or Mounjaro at work?

No. But the question is now common, and insurers are building corporate options around weight management services and medication cover.

If we cover it, will demand blow up?

It can if eligibility is vague or reimbursement is open-ended. Clear rules and a structured pathway tend to keep demand more predictable.

Can we just fund medication and skip support?

You can, but it increases risk and makes outcomes harder to measure. NICE frames these medicines within a broader weight management context with diet and physical activity support, which is a useful design signal.

What's a sensible review point?

NICE uses a 6-month review point in both semaglutide and tirzepatide guidance to decide whether to continue based on response and risk.

Download the GLP-1 Policy Starter Pack

If you're about to write (or rewrite) your GLP-1 position, don't start from a blank page.

Download the "UK Employer GLP-1 Policy Starter Pack":

• decision checklist (pick your policy model fast)
• eligibility and guardrails template (plain English)
• employee FAQ copy
• provider questions
• 10-week pilot scorecard with privacy-safe metrics

If you want to chat about running a pilot (small and controlled is fine), request a pilot here.

← Back to Blog